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Abstract
Background: The aim of the current study was to develop an online calculator to
predict survival after liver resection for intrahepatic cholangiocarcinoma (ICC) based
on the “metro‐ticket” paradigm.
Methods: Between 1990 and 2016, patients who underwent liver resection for ICC
were identified in an international multi‐institutional database. The final multivariable
model of survival was used to develop an online prognostic calculator of survival.
Results: Among 643 patients, actual 5‐year overall survival (OS) after resection for ICC
was 42.7%. On multivariable analysis, CA19‐9> 200 (hazard ratio (HR), 2.62; 95% CI,
2.01‐3.42), sum of the number and largest tumor size >7 (HR, 1.88; 95% CI, 1.46‐2.42),
N1 disease (HR, 2.87; 95% CI, 1.98‐4.16), R1 resection (HR, 1.72; 95% CI, 1.21‐2.46),
poor/undifferentiated tumor grade (HR, 1.74; 95% CI, 1.25‐2.44), major vascular invasion
(HR, 1.47; 95% CI, 1.03‐2.10), and adjuvant chemotherapy (HR, 0.64; 95% CI, 0.45‐0.89)
were significantly associated with survival and were included in the online calculator. The
predictive accuracy of the model was good to very good as the C‐statistics to
predict 5‐year OS was 0.696 in the training dataset and 0.672 with bootstrapping
resamples (n = 5000) in the test dataset.
Conclusion: A novel, online calculator was developed to estimate the 5‐year survival
probability for patients undergoing resection for ICC. This tool could help provide
useful information to guide treatment decision‐making and inform conversations
about prognosis.
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1 | INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) is the second most common
primary liver malignancy after hepatocellular carcinoma (HCC). The
incidence of ICC has been increasing in the United States and worldwide
J Surg Oncol. 2019;120:223-230. wileyonlinelibrary.com/journal/jso © 2019 Wiley Periodicals, Inc. | 223
Drs Sahara, Tsilimigras and Mehta contributed equally to this study.
over the last three decades.1,2 Although surgery remains the best chance
for long‐term survival among patients with ICC, only 30%‐40% of
patients present with resectable disease at the time of diagnosis.3 In
addition, even after curative‐intent resection, prognosis remains poor
with 5‐year overall survival (OS) ranging from 15%‐40%.3 Long‐term
outcomes following surgical resection vary and depend on a wide variety
of factors. In turn, several prognostic schemes have been proposed to
help both physicians and patients define the relative benefit of surgical
resection, as well as estimate life expectancy following surgery.4,5
Although current established staging systems, such as the
American Joint Committee on Cancer (AJCC) staging system are
helpful,6 these schemas are more applicable to a population of
patients. In particular, staging systems typically provide estimates of
aggregate survival data for a group of patients who have comparable
pathological characteristics.6 More recently, there has been an
increased focus on using specific patient‐ and tumor‐level character-
istics to provide individualized survival estimates. To this end, various
groups have advocated for nomograms as a means to integrate
individual‐level variables into a statistical model to predict out-
comes.7-10 The applicability and clinical utility of nomograms are
frequently limited, however, due to their cumbersome nature, as well
as the inability to easily and readily use nomograms in a simple, real‐
world clinical setting. In addition, nomograms typically fail to provide
clear information on a range of survival estimates as clinical and
pathological factors vary.
More recently, several groups have proposed a “metro‐ticket”
approach to estimate survival. First proposed by Mazzaferro
et al,11 the “metro‐ticket” system was based on the concept that
the “cost” (ie, worse survival) was higher the “longer you go” (ie,
expanded indications for surgery). The initial metro‐ticket scheme
predicted survival after liver transplantation among patients with
HCC that exceeded the Milan criteria.11 More recently, an updated
HCC metro‐ticket system incorporated individual tumor charac-
teristics (ie, tumor size and number) and alpha‐fetoprotein (AFP)
levels.12 While the metro‐ticket approach has been applied to
other malignancies such as colorectal liver metastases (CRLM) and
gastric cancer,13,14 its applicability to ICC has never been
investigated. As such, the objective of the current study was to
apply the principles of the metro‐ticket paradigm to patients
undergoing liver resection for ICC. Specifically, we sought to
develop a novel, easy‐to‐use online calculator to predict OS
following resection of ICC based on a metro‐ticket approach that
incorporated tumor characteristics, tumor markers, as well as
histopathologic findings.
2 | METHODS
2.1 | Study population and data collection
Patients undergoing surgical resection for ICC between January 1990
and December 2016 were identified in a multi‐institutional database
incorporating data from 15 tertiary institutions (The Ohio State
University Comprehensive Cancer Center, Columbus, OH; Johns Hopkins
Hospital, Baltimore, MD; Stanford University, Stanford, CA; University of
Virginia, Charlottesville, VS; Winship Cancer Institute, Emory University,
Atlanta, GA; Fundeni Clinical Institute, Bucharest, Romania; Scientific
Institute San Raffaele, Vita‐Salute San Raffaele University, Milan, Italy;
University of Verona, Verona, Italy; Curry Cabral Hospital, Lisbon,
Portugal; Beaujon Hospital, Clichy, France; Erasmus University Medical
Center, Rotterdam, The Netherlands; University of Ottawa, Ontario,
Canada; Eastern Hepatobiliary Surgery Hospital, Shanghai, China;
Yokohama City University School of Medicine, Yokohama, Japan; and
Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia). For
the purpose of this study, only patients with histologically confirmed ICC
who underwent curative‐intent liver resection without extrahepatic
metastasis were included. Patients with macroscopic positive surgical
margins (R2 resection) were excluded, as well as patients who had
missing data that were required for the development of the prognostic
model. The Institutional Review Board of all the participating institutions
approved this study.
Patient demographics and clinicopathologic data were extracted
including age, sex, race, American Society of Anesthesiologist class,
the presence of cirrhosis, preoperative serum level of carbohydrate
antigen (CA) 19‐9, type of resection, number of ICC, tumor size,
lymph nodal status, location of lymph node metastasis, morpholo-
gical type (MF, mass‐forming; IG, intraductal growth; and PI,
periductal infiltrating), tumor grade and margin status, major or
minor vascular invasion, and the presence of perioperative
chemotherapy. Major hepatectomy was defined as the resection
of three or more Couinaud segments.15 Major vascular invasion was
defined as invasion of the first‐ and second‐order branches of the
portal vein or hepatic arteries, or as an invasion of one or more of
the three hepatic veins. In contrast, the microvascular invasion was
defined as intraparenchymal vascular involvement identified on
histological examination.6
2.2 | Statistical analysis
Continuous and categorical variables were presented as medians
(interquartile ranges [IQRs]) and frequency (%), respectively. OS was
defined as the time interval between the date of surgery and date of
death, while time was censored at the date of the last follow‐up for
living patients. Survival curves were estimated using the Kaplan‐
Meier method and differences between curves were investigated
with the logrank test. The association of clinicopathologic variables
with OS was evaluated by using a Cox proportional hazards model.
The final model was described using the hazard ratio (HR) and 95%
confidence interval (CI).
2.3 | Development and validation of the prognostic
model and online application
The final multivariable model was used to develop the prognostic
model and the online application. To assess the predictive ability of
the final model, the c‐index for time‐to‐event data was calculated
with the bootstrapping resample method (n = 5000) using the R
224 | SAHARA ET AL.
CRAN package Hmisc.16 C‐index is an extension of the area under
the receiver operating characteristic curve to survival analysis and
was measured as a continuous value ranging from 0.5 (random
prediction not different than chance) to 1 (perfect prediction).17 The
c‐index results as the probability that, given two randomly selected
patients, the patient who died first had a higher probability of death
based on the predictive model.18 The “shiny: Web Application
Framework for R” package was used to develop a web application:
(https://metroticketicc.shinyapps.io/metroticket_ICC/). For statistical
analysis, the STATA software (Stata Corporation, 2011, MP‐Parallel
Edition) and R CRAN software (v. 3.5.3, 2019) with the packages
survival, shiny, and Hmisc were used.
3 | RESULTS
3.1 | Patient characteristics
Among 1154 patients who underwent hepatectomy for ICC between
1990 and 2016, a total of 643 patients met inclusion criteria and were
included in the analytic cohort. Median patient age at the time of surgery
was 59 years (IQR, 50‐68) and more than half of the patients were male
(n = 382, 59.4%). Τhe majority of patients were non‐Caucasian, non‐
African American (n = 421, 65.5%) and did not have cirrhosis (n = 555,
86.3%). Roughly half of the patients underwent major hepatectomy
(n =323, 50.4%) and most patients had the unilobar disease (n = 549,
85.6%). The median tumor number and largest tumor size were 1 (IQR, 1‐
1) and 5.7 cm (IQR, 4.0‐8.0), respectively, resulting in a median sum of 7.0
(5.0‐9.5). Median preoperative CA19‐9 levels were 45.8UI/mL (IQR,
18.0‐192.7; Table 1). Most patients had an R0 resection (n = 572, 89.2%),
MF or IG morphologic ICC type (n = 565, 91.3%), and well to moderately
differentiated tumors (n = 541, 86.1%); only a small subset had major
vascular invasion (n = 72, 11.2%). On histology, the microvascular invasion
was present in 27.3% (n =175) of patients. A minority of individuals
received adjuvant (n = 131, 20.6%) and neoadjuvant chemotherapy
(n = 43, 6.8%).
3.2 | Clinicopathological factors associated with OS
After a median follow‐up of 21.2 months (IQR, 11.2‐38.9), OS after
liver resection for ICC was 80.3%, 54.3%, and 42.7% at 1, 3,
and 5 years, respectively. On multivariable analysis, after control-
ling for competing factors, preoperative CA19‐9 > 200 (HR, 2.62;
95% CI, 2.01‐3.42) and the sum of lesion number and largest tumor
size >7 (HR, 1.88; 95% CI, 1.46‐2.42) were associated with higher
hazards of death. Perhaps not surprisingly, N1 (HR, 2.87; 95% CI,
1.98‐4.16) and Nx status (HR, 1.68; 95% CI, 1.20‐2.35), R1 resection
(HR, 1.72; 95% CI, 1.21‐2.46), poor/undifferentiated tumor grade
(HR, 1.74; 95% CI, 1.25‐2.44), and major vascular invasion (HR,
1.47; 95% CI, 1.03‐2.10) were also associated with poor OS. In
contrast, receipt of adjuvant chemotherapy was associated with
35% decreased hazards of death (HR, 0.65; 95% CI, 0.45‐0.89;
Table 2).
TABLE 1 Demographic and patient characteristics in the entire
cohort
Variable N (%)




African American 16 (2.5%)
Other 421 (65.5%)
Cirrhosis 88 (13.7%)





Minor resection 318 (49.6%)




Number of tumor nodule, median (IQR) 1 (1‐1)
Tumor size, cm; median (IQR) 5.7 (4.0‐8.0)











MF, IG 565 (91.3%)
PI, MF+PI 54 (8.7%)
Grade
Well to moderate 541 (86.1%)










Abbreviations: CA, carbohydrate antigen; IG, intraductal growth; IQR,
interquartile range; MF, mass‐forming; PI, periductal infiltrating.
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3.3 | Predicting 5‐year OS using the online
calculator
The online model to predict 5‐year OS among patients undergoing
resection for ICC is available at https://metroticket‐icc.shinyapps.io/
metroticket_ICC/. Number and largest size of the tumor, preoperative
CA19‐9 levels, lymph node status, margin status, and grade of tumor
differentiation were included in the online model as “principal
characteristics” (Figure 1A). Moreover, type of resection, presence of
cirrhosis, major and microscopic vascular invasion, as well as receipt of
adjuvant chemotherapy were also included in the model as “additional
information” (Figure 1B). On the basis of the model, a range of survival
outcomes could be estimated following resection of ICC. For example,
a patient with a preoperative CA19‐9 of 200.0 UI/mL who underwent
a resection of a 5 cm, solitary, well‐differentiated ICC and had negative
surgical margins, negative lymph nodes, no evidence of major or
microscopic vascular invasion, and no receipt of adjuvant treatment
after resection had an estimated 5‐year OS of 55% (Figure 1C). In
contrast, a patient with a preoperative CA19‐9 of 400.0 UI/mL who
underwent a resection of a 7 cm, solitary, moderate‐differentiated ICC
and had negative surgical margins, metastatic lymph nodes, no
evidence of microscopic, and major vascular invasion, the presence
of cirrhosis who received adjuvant treatment after major resection
would have an estimated 5‐year OS of 21% (Figure 1D).
3.4 | Predictive performance of the model
To assess the predictive accuracy of the online calculator, patients were
categorized into different subgroups based on the xpredicted 5‐year
OS: class I, >75%; class II, 51‐75%; class III, 26‐50%; and class IV, <25%. In
turn, the actual 5‐year OS was evaluated among the different subgroups:
class I, 70.5% (95% CI, 47.0‐100%); class II, 59.0% (95% CI, 51.0‐68.2%);
class III, 40.8% (95% CI, 32.6‐51.1%), and class IV, 12.9% (95% CI,
7.1‐23.2%; Figure 2). Of note, the predictive accuracy (discrimination) of
the final model was good to very good as the model C‐statistic to predict
5‐year OS was 0.696 in the training dataset and 0.672 with bootstrapping
resamples (n = 5000) in the test dataset.
4 | DISCUSSION
While ICC is an aggressive tumor with generally poor prognosis
following surgical resection, the long‐term prognosis can vary
significantly.2,19-21 Accurate prognostication of long‐term survival
remains important for clinicians to guide treatment decision‐making,
as well as for patients to understand their prognosis. To date, several
prognostic models and nomograms have been developed to
determine the prognosis of patients undergoing surgery for hepato‐
pancreato‐biliary malignancies.22-25 In comparison with the tradi-
tional AJCC staging system, these nomograms are thought to tailor
prognostication based on the individual patient characteristics and
clinicopathological factors, and, thus, have been proposed for a
number of cancers.10,26-30 Nevertheless, the clinical applicability of
nomograms is limited due to the lack of a simple calculator available
for use among clinicians. In addition, many nomograms have suffered
from modest‐to‐poor prognostic discrimination.4 The current study
was important because we developed a novel, easy‐to‐use, online
calculator based on the “metro‐ticket” paradigm to predict 5‐year OS
among patients undergoing surgery for ICC. Of note, factors such as
CA19‐9 > 200, the sum of the number and largest size of tumor >7,
metastatic lymph nodes, R1 resection, poor/undifferentiated tumor
grade, and presence of vascular invasion and adjuvant chemotherapy
were adversely associated with OS. In contrast, only the receipt of






Variable HR 95% CI HR 95% CI
Cirrhosis
No Ref Ref
Yes 1.02 0.74‐1.41 1.27 0.90‐1.80
CA19‐9, UI/mL
≤200 Ref Ref
>200 2.60 2.04‐3.31 2.62 2.01‐3.42
Type of resection
Minor Ref Ref
Major 1.31 1.04‐1.65 0.91 0.67‐1.24
Number summed to size
of tumor nodule
≤7 Ref Ref
>7 1.90 1.49‐2.40 1.88 1.46‐2.42
Lymph node status
N0 Ref Ref
Nx 1.33 0.99‐1.79 1.68 1.20‐2.35
N1 2.78 1.96‐3.94 2.87 1.98‐4.16
Margin status
R0 Ref Ref
R1 1.90 1.37‐2.64 1.72 1.21‐2.46
Grade
Well to moderate Ref Ref
Poor
to undifferentiated
1.74 1.29‐2.37 1.74 1.25‐2.44
Major vascular invasion
No Ref Ref
Yes 1.68 1.21‐2.33 1.47 1.03‐2.10
Microvascular invasion
No Ref Ref
Yes 1.36 1.05‐1.75 1.06 0.78‐1.43
Adjuvant chemotherapy
No Ref Ref
Yes 0.93 0.70‐1.25 0.65 0.45‐0.89
Abbreviations: CA, carbohydrate antigen; CI, confidence interval; HR,
hazard ratio; IQR, interquartile range.
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adjuvant chemotherapy was associated with decreased hazards of
death. By combining the aforementioned variables, along with
cirrhosis—an established prognostic factor for ICC,31-33 we devel-
oped an online calculator that predicted 5‐year OS among patients
undergoing resection for ICC. The model showed a good predictive
ability in the training (C‐statistic = 0.696) and validation
cohorts (C‐statistic = 0.672). Perhaps of more interest, when patients
were categorized in different groups based on their predictive 5‐year
OS, actual OS was similar to OS predicted by the model. To the best
of our knowledge, this is the first study to provide a simple, easy‐to‐
use online calculator to estimate the 5‐year OS probability among
patients undergoing surgery for ICC.
The metro‐ticket concept was first proposed by Mazzaferro
et al11 in an attempt to predict long‐term outcomes of patients
undergoing liver transplantation for HCC. This prognostic tool has
been demonstrated to stratify accurately HCC patients with regard
to long‐term survival, as prognosis worsened with increasing tumor
size and number, just as longer trips on the “metro” result in a higher
“ticket” price. The system was recently updated to incorporate tumor
size, number and AFP as continuous rather than dichotomous
F IGURE 1 Illustration of the online calculator with principal characteristics (A), additional information (B), and the resultant predicted 5‐
year OS (C, D). ICC, intrahepatic cholangiocarcinoma; OS, overall survival [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 2 Kaplan‐Meier curve showing the actual OS of patients
stratified by classes of predicted OS. OS, overall survival
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variables, thus, providing a better prognostic stratification of patients
with HCC.12 Sasaki et al13 recently applied the metro‐ticket concept
using the maximum tumor size and number of lesions to define
prognosis of patients undergoing resection for CRLM. In a different
study, Lu et al14 developed a novel TNM staging system for gastric
cancer based on the same principles. To date, however, no study has
applied the metro‐ticket concept to patients undergoing surgery for
ICC. In the current study, we sought to apply these principles to
predict 5‐year OS among patients undergoing resection for ICC using
a large multi‐institutional database. Of note, among 643 patients
undergoing surgery for ICC, 5‐year OS was 42.7%. When patients
were divided to groups according to their predictive 5‐year OS,
actual survival was similar to the OS predicted by the calculator.
Indeed, patients with predicted 5‐year OS of <25%, 26%‐50%, 51%‐
75%, and >75% had an actual 5‐year OS of 12.9%, 40.8%, 59.0%, and
70.5%, respectively (Figure 2). In contrast to previous studies, which
have included only two or three factors in the prediction of OS,10,26
our calculator assigned weights to each of the variables included in
the multivariable model. Indeed, previous multi‐institutional and
registry analyses have demonstrated that except for tumor size and
number,33-37 other factors such as CA19‐9 levels, margin, and lymph
node status as well as major and microscopic vascular invasion are
important determinants of long‐term outcomes, and, thus, should be
taken into account when predicting the OS of patients with ICC.38-44
As such, our calculator could provide a more accurate prediction of
long‐term outcomes for patients undergoing surgery for ICC.
Recently, there has been a growing interest in the accessibility and
utilization of online calculators by both health care providers and
patients to find information about health promotion and disease
management.45-47 Of note, cancer prognosis is among the leading
topics of information that is sought by both physicians and patients.47
Indeed, Rabin et al47 recently performed a systematic review and noted
that the prognostic calculators have been increasingly utilized by
physicians and patients with prostate, colorectal, breast cancer, and
melanoma. Online prediction tools are particularly relevant in settings
where prognosis of patients can be heterogeneous and dependent on a
range of factors such as in ICC. To this end, an easy‐to‐use web‐based
calculator was created that was able to predict the prognosis of patients
undergoing surgery for ICC. Importantly, by providing information on
tumor characteristics (ie, size, number, and differentiation), tumor
marker (ie, CA19‐9), and histopathological findings (ie, margin and
lymph node status, microvascular invasion), the calculator estimated the
5‐year survival probability (Figure 1). Of note, the predictive ability of
this model was good in both the training (C‐statistic = 0.696) and
validation cohorts (C‐statistic = 0.672), suggesting that this calculator
may be a useful tool for surgeons treating patients with ICC. In
particular, accurate data to risk stratify patients may help identify which
patients may benefit the most from adjuvant therapy.48,49
The current study had several limitations that should be considered
when interpreting the results. As with all retrospective studies, selection
bias may have influenced which patients were offered surgery. In
addition, data used in the prediction model were largely obtained based
on the postoperative factors and thus the calculator would be largely
applicable in estimating long‐term prognosis following surgery. Finally,
information on the response to neoadjuvant therapy and its potential
impact on survival was not included in the model.
In conclusion, long‐term outcomes of patients undergoing curative‐
intent resection for ICC were relatively poor with a 5‐year OS of
approximately 40%. Prognosis of patients was associated with factors
such as tumor size and number, serum CA19‐9 levels, lymph node status,
margin status, and tumor differentiation, major and microscopic vascular
invasion as well as receipt of adjuvant chemotherapy. On the basis of
these factors, a novel, easy‐to‐use online calculator was developed to
estimate the 5‐year survival probability for patients undergoing resection
for ICC. This “metro‐ticket” calculator was able to accurately predict the
actual survival of patients and performed well on internal validation. This
tool could help provide clinicians useful information to guide treatment
decision‐making and help inform conversations about prognosis with
patients after surgical resection of ICC.
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